NOV120101 is primarily utilized in the field of oncology as a potential therapeutic agent. It is being investigated for its efficacy in targeting specific cancer cells, particularly in cases where traditional treatments have shown limited success. The compound is designed to interfere with the signaling pathways that promote tumor growth, thereby inhibiting the proliferation of malignant cells. Research is ongoing to determine its effectiveness in various cancer types, including solid tumors and hematologic malignancies. Additionally, NOV120101 is being explored for its potential to enhance the efficacy of existing chemotherapy regimens, offering a synergistic approach to cancer treatment. Its application in clinical trials aims to establish a new avenue for patients with refractory or advanced-stage cancers.